DK2273996T3 - HUMAN CARDIOVASCULAR PROGENITOR CELLS - Google Patents
HUMAN CARDIOVASCULAR PROGENITOR CELLS Download PDFInfo
- Publication number
- DK2273996T3 DK2273996T3 DK09726362.8T DK09726362T DK2273996T3 DK 2273996 T3 DK2273996 T3 DK 2273996T3 DK 09726362 T DK09726362 T DK 09726362T DK 2273996 T3 DK2273996 T3 DK 2273996T3
- Authority
- DK
- Denmark
- Prior art keywords
- cells
- human
- population
- progenitor cells
- dkk1
- Prior art date
Links
- 230000002526 effect on cardiovascular system Effects 0.000 title claims description 86
- 210000000130 stem cell Anatomy 0.000 title claims description 54
- 210000004027 cell Anatomy 0.000 claims description 180
- 210000002242 embryoid body Anatomy 0.000 claims description 70
- 210000004413 cardiac myocyte Anatomy 0.000 claims description 50
- 102100030074 Dickkopf-related protein 1 Human genes 0.000 claims description 45
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 42
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 42
- 101000864646 Homo sapiens Dickkopf-related protein 1 Proteins 0.000 claims description 41
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 40
- 238000000034 method Methods 0.000 claims description 39
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 claims description 33
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 claims description 33
- 238000012258 culturing Methods 0.000 claims description 30
- 210000002889 endothelial cell Anatomy 0.000 claims description 21
- 108010023082 activin A Proteins 0.000 claims description 18
- 210000004509 vascular smooth muscle cell Anatomy 0.000 claims description 15
- 108010059616 Activins Proteins 0.000 claims description 14
- 102100026818 Inhibin beta E chain Human genes 0.000 claims description 14
- 239000000488 activin Substances 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 14
- 239000004017 serum-free culture medium Substances 0.000 claims description 11
- 238000000684 flow cytometry Methods 0.000 claims description 8
- 238000003306 harvesting Methods 0.000 claims description 8
- 239000002609 medium Substances 0.000 claims description 5
- 239000012679 serum free medium Substances 0.000 claims 5
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 claims 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 38
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 38
- 230000000747 cardiac effect Effects 0.000 description 31
- 230000014509 gene expression Effects 0.000 description 30
- 230000004069 differentiation Effects 0.000 description 22
- 238000011161 development Methods 0.000 description 17
- 230000018109 developmental process Effects 0.000 description 17
- 210000003716 mesoderm Anatomy 0.000 description 17
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 13
- 230000006698 induction Effects 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- 102000013814 Wnt Human genes 0.000 description 12
- 108050003627 Wnt Proteins 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 11
- 239000003112 inhibitor Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 230000009067 heart development Effects 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 8
- 238000010195 expression analysis Methods 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 210000002464 muscle smooth vascular Anatomy 0.000 description 8
- 101100016889 Rattus norvegicus Hes2 gene Proteins 0.000 description 7
- 230000001464 adherent effect Effects 0.000 description 7
- 230000003511 endothelial effect Effects 0.000 description 7
- 239000002243 precursor Substances 0.000 description 7
- 238000003556 assay Methods 0.000 description 6
- 210000001671 embryonic stem cell Anatomy 0.000 description 6
- 230000003394 haemopoietic effect Effects 0.000 description 6
- 229920000609 methyl cellulose Polymers 0.000 description 6
- 239000001923 methylcellulose Substances 0.000 description 6
- 238000004264 monolayer culture Methods 0.000 description 6
- 108010054624 red fluorescent protein Proteins 0.000 description 6
- 238000003757 reverse transcription PCR Methods 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 230000002792 vascular Effects 0.000 description 6
- 210000001900 endoderm Anatomy 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 108010082117 matrigel Proteins 0.000 description 5
- 101710099518 Dickkopf-related protein 1 Proteins 0.000 description 4
- 101001053263 Homo sapiens Insulin gene enhancer protein ISL-1 Proteins 0.000 description 4
- 102100024392 Insulin gene enhancer protein ISL-1 Human genes 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 108010014480 T-box transcription factor 5 Proteins 0.000 description 4
- 102100024755 T-box transcription factor TBX5 Human genes 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 210000002064 heart cell Anatomy 0.000 description 4
- 230000004217 heart function Effects 0.000 description 4
- 238000012744 immunostaining Methods 0.000 description 4
- 210000001161 mammalian embryo Anatomy 0.000 description 4
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- 102000010825 Actinin Human genes 0.000 description 3
- 108010063503 Actinin Proteins 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- 102000004987 Troponin T Human genes 0.000 description 3
- 108090001108 Troponin T Proteins 0.000 description 3
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 3
- 102000044880 Wnt3A Human genes 0.000 description 3
- 108700013515 Wnt3A Proteins 0.000 description 3
- 102000006783 calponin Human genes 0.000 description 3
- 108010086826 calponin Proteins 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 230000037020 contractile activity Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 210000004602 germ cell Anatomy 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 210000001811 primitive streak Anatomy 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 210000002460 smooth muscle Anatomy 0.000 description 3
- 230000003827 upregulation Effects 0.000 description 3
- 230000002861 ventricular Effects 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102000001045 Connexin 43 Human genes 0.000 description 2
- 108010069241 Connexin 43 Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102100029284 Hepatocyte nuclear factor 3-beta Human genes 0.000 description 2
- 102100027875 Homeobox protein Nkx-2.5 Human genes 0.000 description 2
- 101001062347 Homo sapiens Hepatocyte nuclear factor 3-beta Proteins 0.000 description 2
- 101000632197 Homo sapiens Homeobox protein Nkx-2.5 Proteins 0.000 description 2
- 101000713606 Homo sapiens T-box transcription factor TBX20 Proteins 0.000 description 2
- 101000652324 Homo sapiens Transcription factor SOX-17 Proteins 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 102000005604 Myosin Heavy Chains Human genes 0.000 description 2
- 102400000058 Neuregulin-1 Human genes 0.000 description 2
- 108090000556 Neuregulin-1 Proteins 0.000 description 2
- 108010032788 PAX6 Transcription Factor Proteins 0.000 description 2
- 102100037506 Paired box protein Pax-6 Human genes 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 102100036833 T-box transcription factor TBX20 Human genes 0.000 description 2
- 102100030243 Transcription factor SOX-17 Human genes 0.000 description 2
- 102000008790 VE-cadherin Human genes 0.000 description 2
- 230000004156 Wnt signaling pathway Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000001746 atrial effect Effects 0.000 description 2
- 210000003050 axon Anatomy 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 108010018828 cadherin 5 Proteins 0.000 description 2
- 102000028861 calmodulin binding Human genes 0.000 description 2
- 108091000084 calmodulin binding Proteins 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000002458 cell surface marker Substances 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 2
- 230000001332 colony forming effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 210000003981 ectoderm Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000007045 gastrulation Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 210000005003 heart tissue Anatomy 0.000 description 2
- 210000003566 hemangioblast Anatomy 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 210000001020 neural plate Anatomy 0.000 description 2
- 238000000059 patterning Methods 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229960001404 quinidine Drugs 0.000 description 2
- 238000009256 replacement therapy Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- CFMYXEVWODSLAX-QOZOJKKESA-N tetrodotoxin Chemical compound O([C@@]([C@H]1O)(O)O[C@H]2[C@@]3(O)CO)[C@H]3[C@@H](O)[C@]11[C@H]2[C@@H](O)N=C(N)N1 CFMYXEVWODSLAX-QOZOJKKESA-N 0.000 description 2
- 229950010357 tetrodotoxin Drugs 0.000 description 2
- CFMYXEVWODSLAX-UHFFFAOYSA-N tetrodotoxin Natural products C12C(O)NC(=N)NC2(C2O)C(O)C3C(CO)(O)C1OC2(O)O3 CFMYXEVWODSLAX-UHFFFAOYSA-N 0.000 description 2
- 230000025366 tissue development Effects 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 238000011870 unpaired t-test Methods 0.000 description 2
- 108010047303 von Willebrand Factor Proteins 0.000 description 2
- 102100036537 von Willebrand factor Human genes 0.000 description 2
- 229960001134 von willebrand factor Drugs 0.000 description 2
- 101150068520 wnt3a gene Proteins 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 1
- 102000002723 Atrial Natriuretic Factor Human genes 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- 102000002585 Contractile Proteins Human genes 0.000 description 1
- 108010068426 Contractile Proteins Proteins 0.000 description 1
- -1 DKKI Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 101100540419 Danio rerio kdrl gene Proteins 0.000 description 1
- 102100031690 Erythroid transcription factor Human genes 0.000 description 1
- 101710100588 Erythroid transcription factor Proteins 0.000 description 1
- 101150021185 FGF gene Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 102100021374 Hepatocyte nuclear factor 3-gamma Human genes 0.000 description 1
- 108010090007 Homeobox Protein Nkx-2.5 Proteins 0.000 description 1
- 102000012808 Homeobox Protein Nkx-2.5 Human genes 0.000 description 1
- 102100037099 Homeobox protein MOX-1 Human genes 0.000 description 1
- 101000818741 Homo sapiens Hepatocyte nuclear factor 3-gamma Proteins 0.000 description 1
- 101000955035 Homo sapiens Homeobox protein MOX-1 Proteins 0.000 description 1
- 101000652332 Homo sapiens Transcription factor SOX-1 Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010084498 Myosin Heavy Chains Proteins 0.000 description 1
- 101150067565 Nfatc1 gene Proteins 0.000 description 1
- 102100034404 Nuclear factor of activated T-cells, cytoplasmic 1 Human genes 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 1
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102100030248 Transcription factor SOX-1 Human genes 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108010051583 Ventricular Myosins Proteins 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 210000002072 atrial myocyte Anatomy 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000007978 cacodylate buffer Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 230000008045 co-localization Effects 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 230000007831 electrophysiology Effects 0.000 description 1
- 238000002001 electrophysiology Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 210000001174 endocardium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 210000001654 germ layer Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000012933 kinetic analysis Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 230000000921 morphogenic effect Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000004457 myocytus nodalis Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 210000001567 regular cardiac muscle cell of ventricle Anatomy 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 238000009168 stem cell therapy Methods 0.000 description 1
- 238000009580 stem-cell therapy Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000030968 tissue homeostasis Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000006459 vascular development Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0657—Cardiomyocytes; Heart cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/165—Vascular endothelial growth factor [VEGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/415—Wnt; Frizzeled
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Materials For Medical Uses (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4004908P | 2008-03-27 | 2008-03-27 | |
| PCT/US2009/038220 WO2009120762A2 (en) | 2008-03-27 | 2009-03-25 | Human cardiovascular progenitor cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2273996T3 true DK2273996T3 (en) | 2017-03-27 |
Family
ID=41114664
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK09726362.8T DK2273996T3 (en) | 2008-03-27 | 2009-03-25 | HUMAN CARDIOVASCULAR PROGENITOR CELLS |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10077428B2 (enExample) |
| EP (1) | EP2273996B8 (enExample) |
| JP (1) | JP5801187B2 (enExample) |
| AU (1) | AU2009228354B2 (enExample) |
| CA (1) | CA2717962C (enExample) |
| DK (1) | DK2273996T3 (enExample) |
| IL (2) | IL208334A (enExample) |
| WO (1) | WO2009120762A2 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2126045A4 (en) * | 2007-01-30 | 2010-05-26 | Univ Georgia | EARLY MESODERM CELLS, STABLE POPULATION OF MESENDODERM CELLS WITH THE ABILITY TO GENERATE ENDODERM AND MESODERM CELL LINES AND MULTIPOTENTIAL MIGRATION CELLS |
| EP3255142A1 (en) * | 2009-10-19 | 2017-12-13 | Cellular Dynamics International, Inc. | Cardiomyocyte production |
| WO2011090684A2 (en) * | 2009-12-29 | 2011-07-28 | Cornell University | Methods for developing endothelial cells from pluripotent cells and endothelial cells derived |
| WO2011091944A1 (en) * | 2010-01-26 | 2011-08-04 | Université Libre de Bruxelles | Tools for isolating and following cardiovascular progenitor cells |
| AU2010355614B2 (en) | 2010-06-13 | 2015-07-02 | Institute Of Biophysics, Chinese Academy Of Sciences | Methods and compositions for preparing cardiomyocytes from stem cells and uses thereof |
| US9181529B2 (en) | 2010-10-19 | 2015-11-10 | Cellular Dynamics International, Inc. | Titration of differentiation medium components |
| US20140045265A1 (en) * | 2011-02-16 | 2014-02-13 | Salk Institute For Biological Studies | Robust and efficient differentiation of human pluripotent stem cells to multipotent vascular progenitors |
| CA2831609C (en) | 2011-03-30 | 2019-06-11 | Cellular Dynamics International, Inc. | Priming of pluripotent stem cells for neural differentiation |
| GB201109882D0 (en) | 2011-06-13 | 2011-07-27 | Cambridge Entpr Ltd | Population of smooth muscle cells of specific embryonic lineages |
| GB201121101D0 (en) * | 2011-12-08 | 2012-01-18 | Nhs Blood & Transplant | A method of preparing isolated cells and uses |
| EP2826855B1 (en) * | 2012-03-15 | 2018-08-29 | iHeart Japan Corporation | Myocardial sheet |
| CA2886396C (en) * | 2012-07-23 | 2023-08-22 | Institute Of Biophysics, Chinese Academy Of Sciences | Method for inducing pluripotent stem cells to differentiate into ventricular cardiomyocytes in vitro |
| WO2014192925A1 (ja) * | 2013-05-31 | 2014-12-04 | ｉＨｅａｒｔ Ｊａｐａｎ株式会社 | 効率的な内皮細胞の誘導方法 |
| AU2014275130B2 (en) | 2013-06-05 | 2019-09-12 | Reverse Bioengineering, Inc. | Compositions and methods for induced tissue regeneration in mammalian species |
| HK1220992A1 (zh) * | 2013-09-13 | 2017-05-19 | 大学健康网络 | 用於产生心外膜细胞的方法和组合物 |
| US11078462B2 (en) | 2014-02-18 | 2021-08-03 | ReCyte Therapeutics, Inc. | Perivascular stromal cells from primate pluripotent stem cells |
| US10240127B2 (en) | 2014-07-03 | 2019-03-26 | ReCyte Therapeutics, Inc. | Exosomes from clonal progenitor cells |
| GB201412554D0 (en) * | 2014-07-15 | 2014-08-27 | Cambridge Entpr Ltd | In vitro mesodermal differentiation |
| JP2018510649A (ja) | 2015-02-17 | 2018-04-19 | ユニバーシティー ヘルス ネットワーク | 洞房結節様ペースメーカー心筋細胞および心室様心筋細胞を作製および使用するための方法 |
| CN115433707A (zh) | 2015-12-07 | 2022-12-06 | 再生疗法有限公司 | 用于重新衍生不同的多能干细胞衍生的褐色脂肪细胞的方法 |
| US10612002B2 (en) | 2016-02-19 | 2020-04-07 | University Of Washington | Human pluripotent stem cell derived endocardial endothelium |
| US20190017029A1 (en) * | 2016-02-25 | 2019-01-17 | The J. David Gladstone Institutes, a testament trust established under the Will of J. David | Generation of Expandable Cardiovascular Progenitor Cells |
| US20230265391A1 (en) * | 2020-05-08 | 2023-08-24 | University Health Network | Methods and compositions for making and using endocardial cells |
| CN119384700A (zh) | 2022-04-15 | 2025-01-28 | 艾斯本神经科学公司 | 细胞分化状态的分类方法和分化细胞的相关组合物 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5874301A (en) | 1994-11-21 | 1999-02-23 | National Jewish Center For Immunology And Respiratory Medicine | Embryonic cell populations and methods to isolate such populations |
| US5919449A (en) | 1995-05-30 | 1999-07-06 | Diacrin, Inc. | Porcine cardiomyocytes and their use in treatment of insufficient cardiac function |
| US20050021439A1 (en) | 1999-04-09 | 2005-01-27 | Pinga Louis J. | Arcade casino and home investment system |
| EP1412479A4 (en) | 2001-07-12 | 2004-07-28 | Geron Corp | CELLS WITH CARDIOMYOCYTE GENERATION PRODUCED FROM HUMAN PLURIPOTENT STEM CELLS |
| US20030082153A1 (en) | 2001-10-22 | 2003-05-01 | The Government Of The United States Of America | Stem cells that transform to beating cardiomyocytes |
| US20060003446A1 (en) | 2002-05-17 | 2006-01-05 | Gordon Keller | Mesoderm and definitive endoderm cell populations |
| US20050043260A1 (en) | 2003-04-21 | 2005-02-24 | Baylor College Of Medicine | Wnt as a factor for cardiac myogenesis |
| US7452718B2 (en) * | 2004-03-26 | 2008-11-18 | Geron Corporation | Direct differentiation method for making cardiomyocytes from human embryonic stem cells |
| US20050214938A1 (en) * | 2004-03-26 | 2005-09-29 | Gold Joseph D | Cardiac bodies: clusters of spontaneously contracting cells for regenerating cardiac function |
| KR20130099253A (ko) | 2005-06-22 | 2013-09-05 | 제론 코포레이션 | 영장류 다능성 줄기 세포의 심근세포 계통 세포로의 분화 |
| EP1913129A4 (en) * | 2005-06-23 | 2009-06-03 | Sinai School Medicine | POPULATIONS OF CARDIOMYOCYTE CELLS |
-
2009
- 2009-03-25 JP JP2011502014A patent/JP5801187B2/ja active Active
- 2009-03-25 US US12/410,782 patent/US10077428B2/en active Active
- 2009-03-25 DK DK09726362.8T patent/DK2273996T3/en active
- 2009-03-25 WO PCT/US2009/038220 patent/WO2009120762A2/en not_active Ceased
- 2009-03-25 CA CA2717962A patent/CA2717962C/en active Active
- 2009-03-25 EP EP09726362.8A patent/EP2273996B8/en active Active
- 2009-03-25 AU AU2009228354A patent/AU2009228354B2/en active Active
-
2010
- 2010-09-21 IL IL208334A patent/IL208334A/en active IP Right Grant
-
2015
- 2015-08-27 IL IL240870A patent/IL240870B/en active IP Right Grant
-
2018
- 2018-08-09 US US16/059,647 patent/US10947506B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2717962A1 (en) | 2009-10-01 |
| JP2011517563A (ja) | 2011-06-16 |
| IL208334A0 (en) | 2010-12-30 |
| IL208334A (en) | 2015-09-24 |
| WO2009120762A3 (en) | 2009-12-30 |
| WO2009120762A2 (en) | 2009-10-01 |
| EP2273996A2 (en) | 2011-01-19 |
| IL240870B (en) | 2019-08-29 |
| EP2273996B8 (en) | 2017-04-26 |
| AU2009228354A1 (en) | 2009-10-01 |
| JP5801187B2 (ja) | 2015-10-28 |
| EP2273996B1 (en) | 2017-02-22 |
| EP2273996A4 (en) | 2012-02-15 |
| US20090269314A1 (en) | 2009-10-29 |
| CA2717962C (en) | 2019-05-14 |
| US10077428B2 (en) | 2018-09-18 |
| US10947506B2 (en) | 2021-03-16 |
| AU2009228354B2 (en) | 2015-01-22 |
| US20180362931A1 (en) | 2018-12-20 |
| IL240870A0 (en) | 2015-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10947506B2 (en) | Human cardiovascular progenitor cells | |
| Cao et al. | Highly efficient induction and long-term maintenance of multipotent cardiovascular progenitors from human pluripotent stem cells under defined conditions | |
| US8507275B2 (en) | Method of inducing differentiation of embryonic stem cells into hemangioblast | |
| US20210062153A1 (en) | Methods and compositions for generating epicardium cells | |
| CA2718032C (en) | Method for generating primate cardiovascular progenitor cells for clinical use from primate embryonic stem cells or embryonic-like state cells, and their applications | |
| CN103189502A (zh) | 基于sirpa表达富集源自多能干细胞的心肌祖细胞和心肌细胞的方法 | |
| US11607429B2 (en) | Derivation and self-renewal of ISI1+ cells and uses thereof | |
| Davies et al. | Stemistry: the control of stem cells in situ using chemistry | |
| US12492378B2 (en) | Stepwise method of producing various types of cells from pluripotent stem cells | |
| WO2017186273A1 (en) | Derivation and self-renewal of multipotent cells and uses thereof | |
| JP2024531682A (ja) | コミットされた心臓始原細胞の製造方法 | |
| JPWO2019189554A1 (ja) | 心筋細胞成熟促進剤 | |
| Braam et al. | SEVEN |